Literature DB >> 8057032

[Aortic valve replacement in a kidney transplant recipient].

G Matsumiya1, S Nakano, R Shirakura, S Nakata, N Fukushima, H Matsuda.   

Abstract

A 62-year-old man with chronic renal failure, who had been treated with hemodialysis, received a kidney transplant from his son in December 1989. He kept good renal function without any episode of graft rejection under the immunosuppressive therapy with Cyclosporine A (CyA), Predonine (PRD), and Mizoribine. In 1990 he started to have exertional dyspnea, and was diagnosed to have aortic valve regurgitation. He underwent aortic valve replacement in September, 1991. He was treated with continuous infusion of CyA and bolus injection of methylprednisolone from the start of the operation, and returned under the preoperative immunosuppressive therapy after oral intake became possible. On the third post-operative day, the level of serum creatinine elevated. Although we couldn't detect significant changes in subpopulations of peripheral blood lymphocytes, steroid pulse therapy was performed as the possibility of acute rejection was underiable. Serum creatinine returned to normal level in a few days and the postoperative course after that was uneventful. He was discharged on the 30th post-operative day.

Entities:  

Mesh:

Year:  1994        PMID: 8057032

Source DB:  PubMed          Journal:  Nihon Kyobu Geka Gakkai Zasshi        ISSN: 0369-4739


  3 in total

1.  Coronary artery bypass graft in a renal transplant recipient.

Authors:  S Taketani; N Fukushima; S Ohtake; Y Sawa; M Nishimura; H Matsuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2000-08

2.  Coronary bypass surgery after renal transplantation.

Authors:  H Noda; Y Fujimura; H Gohra; K Hamano; T Katoh; K Esato
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-03

3.  Long-Term Clinical Outcomes of Cardiac Surgery for Kidney Transplant Patients.

Authors:  Masahide Komagamine; Tomohiro Nishinaka; Yuki Ichihara; Satoshi Saito; Hiroshi Niinami
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-08-26       Impact factor: 1.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.